medigraphic.com
ISSN 1561-2988 (Print)

2012, Number 4

<< Back Next >>

Rev Cubana Farm 2012; 46 (4)

The redox state of VIH/AIDS patients suffering chronic renal failure and undergoing hemodyalisis

Castaño AO, Gil DL, Agete ED, Caballero GM, Abad LY, Calderón FO, Rodríguez SW, Hernández RD, Tápanes PR

Language: Spanish
References: 43
Page:
PDF size: 111.32 Kb.


ABSTRACT

Introduction: the altered redox balance in chronic renal failure has been considered a contributing factor to morbidity and mortality from this disease and as an AIDS progression-associated factor.
Objective: to assess the redox state in HIV patients suffering chronic renal failure that requires haemodialysis.
Methods: a case-control study was conducted in 20 HIV/AIDS patients with chronic renal failure and in 40 apparently healthy individuals. Estimations of malonildialdehyde, gluthatione, superoxide dismutase, catalase, advanced products from protein oxidation, hydroperoxides and peroxidation potentials, as well as progression markers such as T CD4+ lymphocyte count, viral load and a series of hemochemical and hematological determinations were all made. The analysis was made before, 30 minutes and 240 min after the dialysis. The assumptions of variance equality and variable normality were verified, and accordingly, a parametric or non-parametric test was applied. The result was significant for p< 0,05.
Results: the redox state indicators were found to be altered in the studied patients when they were compared to the supposedly healthy group before hemodialysis. It was shown that the values of malondialdehyde, advanced products from protein oxidation, superoxide dismutase were high and significant whereas catalase and gluthatione had lower values after 240 minutes of dialysis, except for hydroperoxides that did not change. The plasma viral load decreased significantly in this process.
Conclusions: the results suggested that the dialysis in this type of patients favors the oxidative stress, together with the reduction of the plasma viral load. The study grants some methodological value to the management of these patients and to the search for a better quality of life.


REFERENCES

  1. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zocalli C. Oxidative stress in end-stage renal disease: an emerging threat to patients outcome. Nephrol Dial Transplant. 2003;18:1272-80.

  2. Haugen E, Nath KA. The involvement of oxidative stress in the progression of renal injury. Blood Purif. 1999;17:58-65.

  3. Mircescu G. Oxidative stress of chronic kidney disease. Acta Endocrin (Buc). 2008:4(4):433-46.

  4. Zwart LL, Meerman JHN, Commandeur JNM, Vermeulen NPE. Biomarkers of free radical damage. Applications in experimental animals and in humans. Free Rad Biol Med. 1999;26(1/2):202-26.

  5. Ward R, McLeish K. Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs. 2003;27(3):230-6.

  6. Himmelfarb J. Oxidative stress in hemodialysis. Contrib Nephrol. 2008;161:132-7.

  7. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial. 2009;22(6):636-43.

  8. Clermont G, Lecour S, Lahet J, Siohan P, Vergely C, Chevet D, Rifle G, Rochette L. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res. 2000 Aug 18;47(3):618-23.

  9. Samouilidou E, Graspa E. Effect of dialysis on plasma total antioxidant capacity and lipid peroxidation products in patients with end-stage renal failure. Blood Purif. 2003;21:209-12.

  10. Paul JL, Roch-Arveiller M, Man NK, Luong N, Moatti N, Raichvarg D. Influence of uremia on polymorphonuclear leukocytes oxidative metabolism in end-stage renal disease and dialyzed patients. Nephron. 1991;57:428-32.

  11. Biasioli S, Schiavon R, Petrosino L, Cavallini L, Cavalcanti G, De Fanti E, Zambello A, Borin D. Role of cellulosic and noncellulosic membranes in hyperhomocysteinemia and oxidative stress. ASAIO J. 2000 Sep-Oct;46(5):625-34.

  12. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomakers of inflammation and oxidative stress. Kidney Int. 2004;65:2371-9.

  13. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001;12:2747-52.

  14. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001;16:1189-97.

  15. Wratten ML, Tetta C, Ursini F, Sevanian A. Oxidant stress in hemodialysis: prevention and treatment strategies. Kidney Int. 2000;(Supl 76):5126-32.

  16. Ziouzenkova O, Sevanian A. Oxidative modification of low-density lipoprotein (LDL) in HD patients: role in electronegative LDL formation. Blood Purif. 2000;18(3):169-76.

  17. Cachofeiro V, Goicochea M, Garcia de Vinuesa S, Oubina P, Lahera V, Luno J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int. 2008;74:54-9.

  18. Stenvinkel P, Carrero JJ, Axelsson J, Lindhom B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in chronic kidney disease patient: how do new pieces fir into the uremic puzzle? Clin Am Soc Nephrol. 2008;3:505-21.

  19. Kendrick J, Chonchol MB. Non-traditional risk factor for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008;4:672-81.

  20. Winston JA. HIV and CKD epidemiology. Adv Chronic Kidney Dis. 2010;17:19-25.

  21. Novak JE, Szczech LA. Management of HIV infected patients with ESRD. Adv Chron Kid Dis. 2010;17:101-10.

  22. Pasupthi P, Ramachandran T, Sindhu PJ, Saravanan G, Bakthavathsalam G. Enhanced oxidative stress markers and antioxidant imbalance in HIV infection and aids patients. J Sci Res. 2009;1(2):370-80.

  23. Riddles PW, Blakelye RL, Zerner B. Reassessment of Ellman's reagent. Methods Enzymol. 1983;91:49-60.

  24. Erdelmeier I, Gerard MD, Yadan JC, Chaudiere J. Reactions of N methyl-2-phenylindole with malondialdehyde and 4-hydroxialkenals. Mechanistic aspects of the colorimetric assay of lipid peroxidation. Chem Res Toxicol. 1998;11(10):1184-94.

  25. Ozdemirler G, Mehmetcik G, Oztezcan S, Toker G, Sivas A, Uysal M. Peroxidation potential and antioxidant activity of serum in patients with diabetes mellitus and myocardial infarction. Metab Res. 1995;271:194-6.

  26. Witko-Sarsat V, Friedlander M. Advanced oxidation protein product as novel mediators of inflammation and monocytes activation in chronic renal failure. J Immunol. 1998;161:2524-32.

  27. Beyer W, Fridovich I. Assaying for superoxide dismutase activity: Some large consequences of minor changes in conditions. Anal Biochem. 1987;161:559-66.

  28. Clairborne A. Catalase activity. En: Green-Wald RA, ed. Handbook of Methods for Oxygen Radical Research. Boca Ratón, FL: CRC Press Inc; 1986. p. 283-4.

  29. Gil L, Martínez G, González I, Tarinas A, Álvarez A, Giuliani A, et al. Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacol Res. 2003;47:217-24.

  30. Gil L, Lewis L, Martinez G, Tarinas, González I, Alvarez A, et al. Effect of increased dietary micronutrient intake on oxidative stress indicators in HIV/AIDS patients. Int J Vit Nut Res 2005;75(1):19-27.

  31. Haugen E, Nath KA. The involvement of oxidative stress in the progression of renal injury. Blood Purif. 1999;17:58-65.

  32. Dakshinamurty KV, Srinivas Rao, PVLN, Saibaba KSS, Sheela RB, Venkataramana G, Shyam C, Sreekrishna V. Antioxidant status in patients on maintenance hemodialysis. Ind J Nephrol. 2002;12:77-80.

  33. Nissel R, Faraj S, Sommer K, Henning L, van der Giet M, Querfeld U. Oxidative stress markers in young hemodialysis patients- a pilot study. Clin Nephrol. 2008;70(2):135-43.

  34. González M, Puchades MJ, Garcia R, Saéz G, Tormos MC, Miguel A. Effects of hemodialysis therapy on oxidative stress in patients with chronic renal failure. Nefrología. 2006;26(2):218-25.

  35. Jung HH, Choi DH, Lee SH. Serum malondialdehyde and coronary artery disease in hemodialysis patients. Am J Nephrol. 2004;24:537-42.

  36. Ceballos-Picot J, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med. 1996;21:845-53.

  37. Orhan H, van Holland B, Krab B. Mocken J, Vermeulen NP, Holander P, et al. Evaluation of a multiparameter biomarker of oxidative damage in man: increased urinary excretion of lipid, protein and DNA oxidation products after one hour of exercise. Free Radic Res. 2004;38:1269-79.

  38. Tsimikas S. Measures of oxidative stress. Clin Lab Med. 2006;26(3):57190.

  39. Durak I, Kacmaz M, Elgun S, Serdar H. Oxidative stress in patients with chronic renal failure: effects of hemodialysis. Med Princ Pract. 2004;13:84-7.

  40. Dursun E, Ozben T, Suleymanlar G, Dursun B, Yakupoglu G. Effects of hemodialysis on the oxidative stress and antioxidants. Clin Chem Lab Med. 2005;40(10):1009-13.

  41. Ahmad A, Sadat M, Soulati M, Marashian M, Rahbar K, Aziz F. Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease. IJKD. 2009;3:162-7.

  42. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int. 2000;58:2571-8.

  43. Bhogade RB, Suryakar AN, Katkam RV. Effects of antioxidant therapy on oxidative stress with special reference to hemodialysis. Biom Res. 2009;20(2):105-8.




2020     |     www.medigraphic.com